ATRC-101 reacts in vitro with a majority of human ovarian, non-small cell lung, colorectal and breast cancer samples from multiple patients. Its most advanced product candidate, ATRC-101, is a monoclonal antibody with a mechanism of action and target derived from an antibody identified using its discovery platform. The Company is discovering and developing antibody-based therapeutics to treat a range of solid tumor types. is a clinical-stage biopharmaceutical company. In the first four years, the partnership will focus on at least three diseases identified: malaria, HIV/AIDS, and tuberculosis.Ītreca, Inc. Under the terms of the agreement, Atreca will apply its Immune Repertoire Capture(TM) technology in a particular set of infectious diseases and other conditions, and the Company will share with the foundation the results for use in the discovery and development of vaccines, therapeutics, and diagnostics to be deployed in a defined group of countries. The foundation's investment establishes a long-term collaboration between the parties. Atreca recently licensed exclusive rights to the technology for all fields of use from Stanford University. These antibodies both have utility themselves and can be employed to identify the targets of an immune response.Īpplied to human disease, Immune Repertoire Capture(TM) is an engine for the discovery and development of antibody-based therapeutics, vaccines, diagnostics, and research reagents. Immune Repertoire Capture(TM) technology leverages next-generation sequencing to identify rapidly and comprehensively the set of functional antibodies produced in patients during an immune response. announced a collaboration with the Bill & Melinda Gates Foundation to accelerate the discovery and development of novel vaccines and therapeutics for human infectious diseases.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |